Missoula, MT, March 19, 2008 - TSI Health Sciences Inc., an innovator and leading producer of high quality nutraceutical ingredients has announced today that the US Patent and Trademark Office has granted it US Patent 7,338,675, entitled "Fenugreek seed bio-active compositions and methods for extracting same", for its Promilin® ingredient, allowing the company to continue to develop the market for this proprietary product promoting healthy glucose and insulin utilization.

A key provision of the patent involves providing novel compositions and methods for the extraction and separation of bio-active compounds/compositions of 4-hydroxyisoleucine from fenugreek seeds. This unique composition can work either synergistically with insulin, or independently, to stimulate GT-4 receptors located on skeletal muscles, to stimulate glucose transport proteins and facilitate the transport of glucose into muscle cells. Fenugreek and 4-hydroxisoleucine are reasonably well established in this field, but the innovation provides a deeper understanding of glucose metabolism and ultimately a superior product targeting this category. Glycogen is an energy source for exercising muscles. Promilin can help to improve glycogen synthesis thorough metabolism of glucose and carbohydrates.

"The award of the patent is significant, covering both composition and application", explains Dr. Sandy Chien of TSI Health Sciences. "It reaffirms our commitment to investing in innovative ingredients and intellectual property with a long term vision for the market and support of our clients. This patent adds important depth to TSI's Intellectual Property portfolio and allows us to work with our clients to develop innovative, efficacious products based on Promilin® and our patented technology - and it’s also significant recognition of the many years we spent perfecting this technology.”

About Promilin®
TSI Health Sciences’ proprietary, patented ingredient Promilin®, is an extract of bioactive amino acids from fenugreek seeds, that helps to improve glycogen resynthesis*, reduce recovery time* and sustain glycogen stores*. Promilin® is subjected to rigorous in-house physical, analytical and microbial testing and safety research indicates that Promilin is safe and non-toxic, with no known side effects.

About TSI Health Sciences
TSI Health Sciences, (www.tsiinc.com ), has evolved throughout the last decade to focus primarily on in-house, high-end ingredient production and has become a leading developer, producer and marketer of nutraceutical ingredients to the dietary supplement, pharmaceutical and food and beverage industries. With US operations based in Missoula, Mont., TSI was founded in 1996 and has offices worldwide, including a 60-acre, fully integrated manufacturing, research, quality assurance and quality control campus in Jiangyin, China. The company’s comprehensive product range includes botanical, marine and natural product extracts, as well as synthesized compounds. TSI guarantees full-service cGMP manufacturing through TSI Manufacturing Systems, with divisions specializing in small and large-scale botanical and natural product extraction, large-scale chemical synthesis production and secondary processing capabilities

(*These statements have not been evaluated by the Food & Drug Administration. This product is not intended to treat, cure, or prevent any disease.)